APhA
This article was originally published in The Tan Sheet
Executive Summary
Group recently adopted policy encouraging manufacturers and FDA "to transition non-sedating antihistamines from prescription to nonprescription status." Association likely will communicate position during May 11 NDAC meeting on petition to switch Claritin, Allegra and Zyrtec (1"The Tan Sheet" March 19, p. 3)
You may also be interested in...
Antihistamine OTC Switch Petition Slated For NDAC Debate May 11
FDA's decision to bring a citizen petition seeking OTC status of three low- and non-sedating antihistamine drugs before NDAC may be an attempt to apply public pressure on Schering-Plough, Aventis and Pfizer to accelerate any plans they may have to initiate switches on their own.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands